Bicycle Therapeutics plc — Form 8-K Summary
Reporting date: July 18, 2019; the report was signed July 24, 2019. The filing reports board appointments, planned director resignations, committee changes, and related compensation. It does not provide financial statements or operating-period results.
Business Context and Governance Changes
- Janice Bourque and Richard Kender were elected to the board effective July 18, 2019.
- Bourque was appointed a Class I director, Chair of the Nominating and Corporate Governance Committee, and a member of the Audit and Compensation Committees.
- Kender was appointed a Class III director, Chair of the Audit Committee and Compensation Committee, and a member of the newly formed Strategic Committee.
- The company initiated an orderly transition intended to reduce board size. Deborah Harland intends to resign after the September 27, 2019 board meeting; Michael Anstey, Bosun Hau, and Carolyn Ng intend to resign on June 30, 2020.
- The filing states that the planned resignations are not due to disagreements with the company regarding operations, policies, or practices.
Financial Metrics, Liquidity, and Capital Structure
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial-period metrics.
Director Compensation
- Bourque will receive annual cash compensation of $40,000 for board service, plus $8,000 as Nominating and Corporate Governance Committee Chair, $8,500 for Audit Committee service, and $6,500 for Compensation Committee service.
- Kender will receive annual cash compensation of $40,000 for board service, plus $17,000 as Audit Committee Chair, $13,000 as Compensation Committee Chair, and $30,000 for Strategic Committee service.
- Each director is eligible for an initial equity award of 23,798 ordinary shares. The award will vest in equal annual installments over three years, subject to continued service, with full acceleration upon a sale of the company.
- Each director entered into the company’s standard deed of indemnity and is eligible for reimbursement of reasonable board and committee meeting expenses.
Committee Reconstitution and Outlook
- As of July 18, 2019, the Audit Committee consisted of Kender as Chair, Bourque, and Kate Bingham.
- The Compensation Committee consisted of Kender as Chair and Bourque.
- The Nominating and Corporate Governance Committee consisted of Bourque as Chair and Bingham.
- The Strategic Committee consisted of Kevin Lee, Kender, and Pierre Legault.
- The filing provides no financial guidance, operating outlook, or forecast.
Important Facts to Verify
- Confirm the effective dates and completion of the announced director resignations.
- Confirm the future grant date, valuation, and final terms of the 23,798-share initial awards.
- Review subsequent filings for the final board size and committee composition.
- Note the filing’s internal date inconsistency: the event is reported as July 18, 2019, while the attached press release and signature are dated July 24, 2019.